429 results about "Beta cell" patented technology

The methods include selectively reducing or expanding T cells according to the antigenic specificity of the T cells. Therefore, the present invention can be used to reduce or eliminate pathogenic T cells that recognize autoantigens, such as beta cell specific T cells. As such, the present invention can be used to prevent, treat or ameliorate autoimmune diseases such as IDDM. Furthermore, the present invention can be used to expand desirable T cells, such as anti-pathogenic T cells to prevent, treat and / or ameliorate autoimmune diseases.

A human immature endocrine cell population and methods for making an immature endocrine cell population are provided. Specifically, immature beta cells and methods for production of immature beta cells are described. Immature beta cells co-express INS and NKX6.1 and are uni-potent and thereby develop into mature beta cells when implanted in vivo. The mature beta cells in vivo are capable of producing insulin in response to glucose stimulation.

Disclosed herein are methods, compositions, kits, and agents useful for inducing β cell maturation, and isolated populations of SC-β cells for use in various applications, such as cell therapy.

A human immature endocrine cell population and methods for making an immature endocrine cell population are provided. Specifically, immature beta cells and methods for production of immature beta cells are described. Immature beta cells co-express INS and NKX6.1 and are uni-potent and thereby develop into mature beta cells when implanted in vivo. The mature beta cells in vivo are capable of producing insulin in response to glucose stimulation.

Advanced Bioreactor Cell Culture Technology presents a method of cell culturing and bioprocessing incorporating molecular biology techniques, advanced process control methodology, and a process control interface applied to a two liquid phase cell culture bioreactors to proliferate, grow, and expand non-differentiated precursor cells, embryonic stem (ES) cells, endocrine progenitor cells, pancreatic progenitor cells, pancreatic stem cells, pancreatic duct epithelial cells, nestin-positive islet-derived progenitor cells (NIPs), or pluripotent non-embryonic stem (PNES) cells in the bioreactor, and influence, stimulate, and induce the non-differentiated precursors and progenitors into fully differentiated beta cell phenotypes; including microprocessor control of cell culture process variables and data acquisition during bioprocessing. The invention may be applied to precursors and progenitor cells either transgenic or non-transgenic derived from animals and mammals.

Disclosed herein are methods, compositions, kits, and agents useful for inducing β cell maturation, and isolated populations of SC-β cells for use in various applications, such as cell therapy.

A cell composition of endocrine progenitor cells derived from mammalian pancreatic islet cells that can be trans-planted into a diabetic patient such that the cells of the cell composition differentiates into functioning insulin-producing beta cells.

The invention provides a pegylated exenatide ramification (Exendin-4-Cys-PEG (polyethylene glycol)) and the use of the pegylated exenatide ramification, belonging to the technical field of the preparation and the application of a polypeptide drug. A preparation method of the pegylated exenatide ramification provided by the invention comprises the following steps of: introducing a cysteine at the C-end of exenatide, and coupling maleic acylamino polyethylene glycol, so that the pegylated exenatide ramification can be formed. The pegylated exenatide ramification provided by the invention has slow clearance rate in the blood circulation and prolonged half-life period, and can be used for preparing the related illness treatment drugs for reducing the blood sugar, reducing the ingestion, reducing the gastrointestinal emptying, increasing the beta cell quantity or reducing the gastrointestinal motility.

Provided herein are methods for the in vitro differentiation of induced pluripotent stem cells, which have been expanded and / or maintained under defined conditions, into endodermal precursor cells (EPCs) that are capable of producing mono-hormonal beta cells.

The invention discloses a mesenchymal stem cell injection, a preparation method and application of the mesenchymal stem cell injection in preparing a medicine for treating diabetes; the mesenchymal stem cells are derived from human umbilical cord and placenta; the mesenchymal stem cell injection consists of components: human mesenchymal stem cells, human albumin, low molecular heparin calcium, compound amino acid, vitamin C of 0.5% and dissolving medium; and the dissolving medium can be a compound electrolyte solution or glucose or normal saline. According to the mesenchymal stem cell injection, the preparation method and the application of the mesenchymal stem cell injection in preparing the medicine for treating the diabetes, the mesenchymal stem cell injection is used for repairing injured islet beta cells, and the blood sugar is reduced by secretion of the endogenous insulin, therefore, a purpose of foundational treating the diabetes is achieved. A disease course of the diabetes can be reversed, patients are helped in escaping out of inconvenience and toxic and side effects of taking the endogenous drug and injecting the insulin as well as serious complications caused by poor control of the blood sugar; and the 1-type and 2-type diabetes are treated thoroughly.

Methods and compositions for treating diabetes mellitus in a patient in need thereof are provided. The methods include administering to a patient a composition providing a gastrin / CCK receptor ligand, e.g., a gastrin, and / or an epidermal growth factor (EGF) receptor ligand, e.g., TGF-alpha, in an amount sufficient to effect differentiation of pancreatic islet precursor cells to mature insulin-secreting cells. The composition can be administered systemically or expressed in situ by cells transgenically supplemented with one or both of a gastrin / CCK receptor ligand gene, e.g., a preprogastrin peptide precursor gene and an EGF receptor ligand gene, e.g., a TGF-alpha gene. The methods also include transplanting into a patient cultured pancreatic islets in which mature insulin-secreting beta cells are proliferated by exposure to a gastrin / CCK receptor ligand and an EGF receptor ligand.

The present invention relates to the phytocannabinoid tetrahydrocannabivarin (THCV) for use in the protection of pancreatic islet cells. Preferably the pancreatic islet cells to be protected are beta cells. More preferably the protection of the pancreatic islet cells maintains insulin production at levels which are able to substantially control or improve control of blood glucose levels in a patient.

Methods and compositions are described for the treatment of type I insulin-dependent diabetes mellitus and other conditions using newly identified stem cells that are capable of differentiation into a variety of pancreatic islet cells, including insulin-producing beta cells, as well as hepatocytes. Nestin has been identified as a molecular marker for pancreatic stem cells, while cytokeratin-19 serves as a marker for a distinct class of islet ductal cells. Methods are described whereby nestin-positive stem cells can be isolated from pancreatic islets and cultured to obtain further stem cells or pseudo-islet like structures. Methods for ex vivo differentiation of the pancreatic stem cells are disclosed. Methods are described whereby pancreatic stem cells can be isolated, expanded, and transplanted into a patient in need thereof, either allogeneically, isogeneically or xenogenically, to provide replacement for lost or damaged insulin-secreting cells or other cells.

The invention relates to a composition for immunologically diagnosing type I diabetes, which contains specific IGRP antigen and ZnT8 antigen of an islet beta cell or is selected from one of common antigens GAD65 and IA-2 or the combination of the antigens GAD65 and IA-2.